CTLA4 and Autoimmunity: Given the marked response of P1 to Abatacept (CTLA-4-Ig) treatment enabling clinical disease remission (Fig. 1c–e), we hypothesized that autoimmunity in DEF6 deficiency may be linked to aberrant CTLA-4 regulation.